Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-05-30 DOI:10.2147/ccid.s468268

Fabrizio Martora, Maria Carmela Annunziata, Luca Potestio, Teresa Battista, Angelo Ruggiero, Matteo Megna

{"title":"Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report","authors":"Fabrizio Martora, Maria Carmela Annunziata, Luca Potestio, Teresa Battista, Angelo Ruggiero, Matteo Megna","doi":"10.2147/ccid.s468268","DOIUrl":null,"url":null,"abstract":"Abstract: This case study outlines the management of a 24-year-old male with a history of juvenile nephronophthisis who underwent renal transplantation at age 12 and later required dialysis at 18 due to chronic rejection and hypertension. Subsequently, the patient developed severe Hidradenitis Suppurativa (HS) affecting the axillary, groin, and gluteal regions. Despite undergoing various systemic and intravenous antibiotic therapies, as well as Adalimumab treatment, the HS remained refractory. Adalimumab was discontinued due to a detected ejection fraction of 45% during cardiologic follow-up, likely due to COVID-19 related myocarditis. Following this, the patient was initiated on secukinumab therapy, initially undergoing an induction phase followed by maintenance dosing. Significant improvements were observed in quality of life, pain scores, and HS activity after 5 weeks of secukinumab therapy, with sustained benefits at the 6-month follow-up. Secukinumab was well tolerated, with no reported adverse events. This case underscores the effectiveness and safety of secukinumab as a therapeutic option for refractory HS, particularly in patients with comorbidities such as renal transplant recipients. Keywords: hidradenitis suppurativa, Adalimumab, antibiotic, Secukinumab ","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/ccid.s468268","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: This case study outlines the management of a 24-year-old male with a history of juvenile nephronophthisis who underwent renal transplantation at age 12 and later required dialysis at 18 due to chronic rejection and hypertension. Subsequently, the patient developed severe Hidradenitis Suppurativa (HS) affecting the axillary, groin, and gluteal regions. Despite undergoing various systemic and intravenous antibiotic therapies, as well as Adalimumab treatment, the HS remained refractory. Adalimumab was discontinued due to a detected ejection fraction of 45% during cardiologic follow-up, likely due to COVID-19 related myocarditis. Following this, the patient was initiated on secukinumab therapy, initially undergoing an induction phase followed by maintenance dosing. Significant improvements were observed in quality of life, pain scores, and HS activity after 5 weeks of secukinumab therapy, with sustained benefits at the 6-month follow-up. Secukinumab was well tolerated, with no reported adverse events. This case underscores the effectiveness and safety of secukinumab as a therapeutic option for refractory HS, particularly in patients with comorbidities such as renal transplant recipients.

Keywords: hidradenitis suppurativa, Adalimumab, antibiotic, Secukinumab

查看原文本刊更多论文

塞库单抗治疗血液透析患者的严重湿疹：每两周服用 300 毫克的疗效和安全性 - 病例报告

摘要：本病例研究概述了一名 24 岁男性患者的治疗情况，该患者有幼年肾炎病史，12 岁时接受了肾移植手术，18 岁时因慢性排斥反应和高血压而需要透析。随后，患者患上了严重的腋窝、腹股沟和臀部湿疹（HS）。尽管接受了各种全身和静脉抗生素治疗以及阿达木单抗治疗，但HS仍然难治。阿达木单抗被停用，原因是在心脏随访期间检测到患者的射血分数为45%，这很可能是与COVID-19相关的心肌炎所致。随后，患者开始接受secukinumab治疗，最初为诱导阶段，随后为维持阶段。接受赛库单抗治疗5周后，患者的生活质量、疼痛评分和HS活动均有显著改善，随访6个月后，疗效持续显现。塞库单抗的耐受性良好，没有不良反应报告。本病例强调了赛库单抗作为难治性HS治疗选择的有效性和安全性，尤其是对肾移植受者等合并症患者。关键词：化脓性扁桃体炎阿达木单抗抗生素赛库单抗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.